Idifarma invests in automatic capsule filling capabilities
Investment enables the CDMO to provide a one-stop-shop service from lab-scale development to manufacturing of clinical batches and dossier compilation to specialised commercial manufacturing.
Idifarma, a Spanish contract development and manufacturing organisation (CDMO) has expanded its GMP manufacturing offering with an investment in automatic capsule filling equipment.
Idifarma has acquired a Bosch GKF-702 capsule filling machine, capable of manufacturing 3,000-42,000 capsules per hour. The new equipment will be installed at the CDMO’s EU-GMP approved plant in Pamplona, Spain, in early 2017.
Commenting on the investment, Luis Oquiñena, general manager and co-founder of Idifarma says: “This is a significant milestone in our journey so far, helping us to become a leading CDMO for small-scale niche products in solid oral forms.
“Idifarma will continue to keep its contract manufacturing focus on specialised, low-volume pharmaceutical products where we can add real value to our clients’ projects involving innovative drugs and niche generics.
“This investment will also include the enlargement of our GMP plant with new rooms and capacity to handle high potency drugs, another clear differentiation and focus area for Idifarma.”
In addition to improving Idifarma’s contract manufacturing capabilities, the GKF-702 will also feature a 'lab kit', enabling the use of the machine during pharmaceutical development, resulting in a more efficient use of APIs and less wastage.
The new machine will benefit from other equipment that is already installed at Idifarma’s GMP plant including a Hüttlin Oyster high-shear mixer and dryer for wet granulation processes, bin blenders with capacity up to 70 kg and a Clinipack IMA blistering machine, with the ability to work with Alu/Alu or any thermo-formable material. Idifarma can also handle narcotics and low-humidity requirements.
Luis Oquiñena continued: “We are confident that this new investment will not only attract clients interested in production, but also contract development projects in hard capsule form in the coming months.
“Our customers can now benefit from a one-stop-shop service from lab-scale development to manufacturing of clinical batches and dossier compilation to specialised commercial manufacturing,” added Luis.
The investment in capsule filling equipment coincides with the 15th anniversary of Idifarma, which will grow its revenue in 2016 by over 25%. The team recently reached 100 people, with 50% of business now coming from outside of Spain.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance